SH00 Stock Overview
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Shionogi & Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6.70 |
| 52 Week High | JP¥8.00 |
| 52 Week Low | JP¥6.07 |
| Beta | 0.29 |
| 11 Month Change | -2.43% |
| 3 Month Change | -0.50% |
| 1 Year Change | -7.80% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| SH00 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -1.2% | -0.02% |
| 1Y | -7.8% | -20.1% | 8.2% |
Return vs Industry: SH00 exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: SH00 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| SH00 volatility | |
|---|---|
| SH00 Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SH00 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SH00's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1878 | 4,959 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
| SH00 fundamental statistics | |
|---|---|
| Market cap | €11.05b |
| Earnings (TTM) | €958.63m |
| Revenue (TTM) | €2.60b |
11.5x
P/E Ratio4.3x
P/S RatioIs SH00 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SH00 income statement (TTM) | |
|---|---|
| Revenue | JP¥418.51b |
| Cost of Revenue | JP¥59.85b |
| Gross Profit | JP¥358.66b |
| Other Expenses | JP¥204.09b |
| Earnings | JP¥154.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 181.70 |
| Gross Margin | 85.70% |
| Net Profit Margin | 36.93% |
| Debt/Equity Ratio | 0% |
How did SH00 perform over the long term?
See historical performance and comparison